Literature DB >> 19494330

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.

Thomas Lindenstrøm1, Else Marie Agger, Karen S Korsholm, Patricia A Darrah, Claus Aagaard, Robert A Seder, Ida Rosenkrands, Peter Andersen.   

Abstract

Improved vaccines capable of promoting long-term cellular immunity are urgently required for a number of diseases that remain global health problems. In the present study, we demonstrate that a tuberculosis subunit vaccine, Ag85B-ESAT-6/CAF01 (where ESAT-6 is early secreted antigenic target of 6 kDa and CAF01 is cationic adjuvant formulation 01), induces very robust memory CD4 T cell responses that are maintained at high levels for >1 year postvaccination. This long-term, vaccine-induced memory response protects against a challenge with Mycobacterium tuberculosis at levels that are comparable to or better than those of bacillus Calmette-Guérin. Characterization of the CD4 memory T cells by multicolor flow cytometry demonstrated that the long-lived memory population consisted almost exclusively of TNF-alpha(+)IL-2(+) and IFN-gamma(+)TNF-alpha(+)IL-2(+) multifunctional T cells. In addition, memory cells isolated >1 year postvaccination maintained a strong, vaccine-specific proliferative potential. Long-term memory induced by the BCG vaccine contained fewer multifunctional T cells and was biased toward effector cells mainly of the TNF-alpha(+)IFN-gamma(+)-coexpressing subset. Ag85B-ESAT-6/CAF01 vaccination very efficiently sustained multifunctional CD4 T cells that accumulated at the site of infection after M. tuberculosis challenge, whereas the response in unvaccinated animals was characterized by CD4 effector T cells. Our data demonstrate that adjuvanted subunit vaccines can promote long-term protective immune responses characterized by high levels of persisting multifunctional T cells and that the quality and profile of this response is sustained postinfection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494330     DOI: 10.4049/jimmunol.0801592

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  182 in total

1.  In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression.

Authors:  Swarali Kurle; Madhuri Thakar; Ashwini Shete; Ramesh Paranjape
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

2.  Polyfunctional responses by human T cells result from sequential release of cytokines.

Authors:  Qing Han; Neda Bagheri; Elizabeth M Bradshaw; David A Hafler; Douglas A Lauffenburger; J Christopher Love
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 3.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

4.  Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment.

Authors:  Uma Shanmugasundaram; Allison N Bucsan; Shashank R Ganatra; Chris Ibegbu; Melanie Quezada; Robert V Blair; Xavier Alvarez; Vijayakumar Velu; Deepak Kaushal; Jyothi Rengarajan
Journal:  JCI Insight       Date:  2020-07-23

5.  Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection.

Authors:  Jonathan R Kurtz; Hailey E Petersen; Daniel R Frederick; Lisa A Morici; James B McLachlan
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

7.  Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination.

Authors:  Mathias Streitz; Stephan Fuhrmann; Fiona Powell; Ali Quassem; Laurel Nomura; Holden Maecker; Peter Martus; Hans-Dieter Volk; Florian Kern
Journal:  J Infect Dis       Date:  2010-12-24       Impact factor: 5.226

8.  CD4+ T cell persistence and function after infection are maintained by low-level peptide:MHC class II presentation.

Authors:  Ryan W Nelson; James B McLachlan; Jonathan R Kurtz; Marc K Jenkins
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

9.  Synthesis and immunogenicity of the Mycobacterium tuberculosis arabinomannan-CRM197 conjugate.

Authors:  Yunsong Chang; Xin Meng; Yaxin Li; Jianmei Liang; Tingshen Li; Demei Meng; Tao Zhu; Peng Yu
Journal:  Medchemcomm       Date:  2019-04-02       Impact factor: 3.597

Review 10.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.